Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.940 +0.150 (+8.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
From Enveric Biosciences
Via Business Wire
News headline image
These stocks are gapping in today's session ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Friday. ↗
Wondering what's happening in Friday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
From Enveric Biosciences
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million. 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Wednesday? ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Participation in 2025 BIO International Convention
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
From Enveric Biosciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.